Early ablation of newly diagnosed paroxysmal atrial fibrillation (NEWPaAF) versus newly diagnosed persistent atrial fibrillation (NEWPeAF): Comparison of patient populations and ablation outcomes.

Introduction: Little is known about very early atrial fibrillation (AF) ablation after first AF detection.

Methods: We evaluated patients with AF ablation <4 months from newly diagnosed paroxysmal AF (NEWPaAF) and newly diagnosed persistent AF (NEWPeAF). We compared the two patient populations and compared ablation outcomes to those undergoing later ablation.

Very long term outcomes of atrial fibrillation ablation.

Background: Little is known about the very long term durability of atrial fibrillation (AF) ablation.

Objective: The purpose of this study was to evaluate very long term AF ablation outcomes.

Methods: We followed 5200 patients undergoing 7145 ablation procedures.

SIMENGINE: a low-cost, high-performance platform for embedded biophysical simulations.

Numerical simulations of dynamical systems are an obvious application of high-performance computing. Unfortunately, this application is underutilized because many modelers lack the technical expertise and financial resources to leverage high-performance computing hardware. Additionally, few platforms exist that can enable high-performance computing with real-time guarantees for inclusion into embedded systems--a prerequisite for working with medical devices.

Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure.

Twenty-one patients with heart failure (New York Heart Association [NYHA] class II to IV) received a 24-hour infusion of enoximone followed by a 12-hour washout period. Patients were randomly assigned to one of four treatment groups. Groups I to III received an 0.

Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure.

Enoximone is a phosphodiesterase inhibitor, which has been studied extensively for use in the management of patients with moderate-to-severe heart failure. The authors have studied the absorption and disposition kinetics of enoximone and its primary metabolite, enoximone sulfoxide, after both single oral doses of enoximone and at steady-state after short-term chronic oral therapy. A total of ten patients (two female, eight male) with moderate-to-severe heart failure (NYHA class II-IV) were enrolled into the study after giving written informed consent.